There is a clear need for a well-designed, definitive random- ized trial of target-driven glucose control in UA/NSTEMI patients with meaningful clinical endpoints so that glucose treatment thresholds and glucose targets can be determined. Until such a trial is completed, and on the basis of the balance of current evidence,157 159 the writing group concluded that it was prudent to change the recommendation for the use of insulin to control blood glucose in UA/NSTEMI from a more stringent to a more moderate target range in keeping with the recent 2009 STEMI and PCI focused update (Class IIa, LOE: B)154 and recommend treatment for hyperglycemia 180 mg/dL while avoiding hypoglycemia. The writing group believed that the 2007 recommendation4 regarding long-term glycemic control targets failed to reflect recent data casting doubt on a specific ideal goal for the management of diabetes in patients with UA/NSTEMI. Diabetes is another characteristic associated with high risk for adverse outcomes after UA/NSTEMI. The 2007 UA/ NSTEMI guidelines4 state that patients with diabetes are at high risk and in general should be treated similarly to patients with other high-risk features. However, the 2012 writing group noted that diabetes was not listed as a high-risk feature for which an invasive strategy was specifically preferred, in contrast to the inclusion of chronic kidney disease (CKD) and diabetes mellitus as characteristics favoring an invasive approach in the 2007 European Society of Cardiology guide- lines for management of UA/NSTEMI.160 To revisit this question for diabetes, the writing group reviewed results of the published analysis of patients with diabetes in the FRISC-II (FRagmin and Fast Revascularization during InSta- bility in Coronary artery disease) trial.72 Overall, the FRISC- II trial demonstrated a benefit with invasive management compared with conservative management in patients with UA/NSTEMI. 